Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques

被引:34
作者
Garber, David A. [1 ,2 ]
O'Mara, Leigh A. [1 ]
Gangadhara, Sailaja [1 ]
McQuoid, Monica [1 ]
Zhang, Xiugen [1 ]
Zheng, Rui [1 ]
Gill, Kiran [1 ]
Verma, Meena [1 ]
Yu, Tianwei [1 ]
Johnson, Brent [1 ]
Li, Bing [1 ]
Derdeyn, Cynthia A. [1 ,3 ]
Ibegbu, Chris [1 ]
Altman, John D. [1 ,4 ]
Hunter, Eric [1 ,3 ]
Feinberg, Mark B. [1 ,2 ,4 ,5 ]
机构
[1] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Med, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
[4] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[5] Merck Vaccines, West Point, PA USA
关键词
T-CELL RESPONSES; I CLINICAL-TRIAL; PHASE-1; SAFETY; EFFICACY TRIAL; DOUBLE-BLIND; DNA PRIME; MVA; PROTEIN; INFECTION; RECEPTOR;
D O I
10.1128/JVI.00246-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Modified vaccinia virus Ankara (MVA) is a safe, attenuated orthopoxvirus that is being developed as a vaccine vector but has demonstrated limited immunogenicity in several early-phase clinical trials. Our objective was to rationally improve the immunogenicity of MVA-based HIV/AIDS vaccines via the targeted deletion of specific poxvirus immune-modulatory genes. Vaccines expressing codon-optimized HIV subtype C consensus Env and Gag antigens were generated from MVA vector backbones that (i) harbor simultaneous deletions of four viral immune-modulatory genes, encoding an interleukin-18 (IL-18) binding protein, an IL-1 beta receptor, a dominant negative Toll/IL-1 signaling adapter, and CC-chemokine binding protein (MVA Delta 4-HIV); (ii) harbor a deletion of an additional (fifth) viral gene, encoding uracil-DNA glycosylase (MVA Delta 5-HIV); or (iii) represent the parental MVA backbone as a control (MVA-HIV). We performed head-to-head comparisons of the cellular and humoral immune responses that were elicited by these vectors during homologous prime-boost immunization regimens utilizing either high-dose (2 x 10(8) PFU) or low-dose (1 x 10(7) PFU) intramuscular immunization of rhesus macaques. At all time points, a majority of the HIV-specific T cell responses, elicited by all vectors, were directed against Env, rather than Gag, determinants, as previously observed with other vector systems. Both modified vectors elicited up to 6-fold-higher frequencies of HIV-specific CD8 and CD4 T cell responses and up to 25-fold-higher titers of Env (gp120)-specific binding (nonneutralizing) antibody responses that were relatively transient in nature. While the correlates of protection against HIV infection remain incompletely defined, our results indicate that the rational deletion of specific genes from MVA vectors can positively alter their cellular and humoral immunogenicity profiles in nonhuman primates.
引用
收藏
页码:12605 / 12615
页数:11
相关论文
共 87 条
[1]   Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors [J].
Alcamí, A ;
Khanna, A ;
Paul, NL ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :949-959
[2]   A mechanism for the inhibition of fever by a virus [J].
Alcami, A ;
Smith, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :11029-11034
[3]   A SOLUBLE RECEPTOR FOR INTERLEUKIN-1-BETA ENCODED BY VACCINIA VIRUS - A NOVEL MECHANISM OF VIRUS MODULATION OF THE HOST RESPONSE TO INFECTION [J].
ALCAMI, A ;
SMITH, GL .
CELL, 1992, 71 (01) :153-167
[4]   The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN [J].
Alcamí, A ;
Symons, JA ;
Smith, GL .
JOURNAL OF VIROLOGY, 2000, 74 (23) :11230-11239
[5]   Duration of humoral immunity to common viral and vaccine antigens [J].
Amanna, Ian J. ;
Carlson, Nichole E. ;
Slifka, Mark K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1903-1915
[6]  
[Anonymous], AIDS EP UPD
[7]   The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses [J].
Antoine, G ;
Scheiflinger, F ;
Dorner, F ;
Falkner, FG .
VIROLOGY, 1998, 244 (02) :365-396
[8]   Structure and function of A41, a vaccinia virus chemokine binding protein [J].
Bahar, Mohammad W. ;
Kenyon, Julia C. ;
Putz, Mike M. ;
Abrescia, Nicola G. A. ;
Pease, James E. ;
Wise, Emma L. ;
Stuart, David I. ;
Smith, Geoffrey L. ;
Grimes, Jonathan M. .
PLOS PATHOGENS, 2008, 4 (01) :0055-0068
[9]   Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys [J].
Barouch, Dan H. ;
Liu, Jinyan ;
Li, Hualin ;
Maxfield, Lori F. ;
Abbink, Peter ;
Lynch, Diana M. ;
Iampietro, M. Justin ;
SanMiguel, Adam ;
Seaman, Michael S. ;
Ferrari, Guido ;
Forthal, Donald N. ;
Ourmanov, Ilnour ;
Hirsch, Vanessa M. ;
Carville, Angela ;
Mansfield, Keith G. ;
Stablein, Donald ;
Pau, Maria G. ;
Schuitemaker, Hanneke ;
Sadoff, Jerald C. ;
Billings, Erik A. ;
Rao, Mangala ;
Robb, Merlin L. ;
Kim, Jerome H. ;
Marovich, Mary A. ;
Goudsmit, Jaap ;
Michael, Nelson L. .
NATURE, 2012, 482 (7383) :89-U115
[10]   Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya [J].
Bejon, Philip ;
Ogada, Edna ;
Mwangi, Tabitha ;
Milligan, Paul ;
Lang, Trudie ;
Fegan, Greg ;
Gilbert, Sarah C. ;
Peshu, Norbert ;
Marsh, Kevin ;
Hill, Adrian V. S. .
PLOS ONE, 2007, 2 (08)